Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction

被引:38
作者
Capes, SE
Gerstein, HC
Negassa, A
Yusuf, S
机构
[1] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada
[2] Hamilton Civ Hosp, Res Ctr, Prevent Cardiol & Therapeut Res Program, Hamilton, ON, Canada
关键词
D O I
10.2337/diacare.23.3.377
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Clinical proteinuria is a risk factor for both end-stage renal disease and car cardiovascular disease. The prevalence of clinical proteinuria, its correlates and predictive value, and the effect of ACE inhibitors in preventing clinical proteinuria in diabetic and nondiabetic patients with left ventricular (LV) dysfunction are unknown. RESEARCH DESIGN AND METHODS - The Studies of Left Ventricular Dysfunction (SOLVD) trials were analyzed to determine the baseline distribution of clinical proteinuria and related cardiovascular risk factors, the effect of baseline proteinuria on the risk of hospitalization for congestive heart failure (CHF) and mortality): and the effect of enalapril in preventing new clinical proteinuria. RESULTS - A total of 5,487 out of 6,797 SOLVD participants (81%) were assessed for proteinuria at baseline. A total of 177 patients (3.2%) had baseline proteinuria. These patients had significantly higher systolic (137 vs. 125 mmHg, P less than or equal to 0.001) and diastolic (83 vs. 77 mmHg, P I 0.001) blood pressure levels, a higher prevalence of diabetes (41 vs. 18%, P less than or equal to: 0.001), a lower ejection fraction (26.2 vs. 27.3%, P less than or equal to 0.05), and greater degree of CHF (New York Heart Association [NYHA] class III/IV in 22 rs. 10%, P less than or equal to 0.001) than patients without baseline proteinuria. Patients with baseline proteinuria also had higher rates of hospitalization for CHF (relative risk 1.81 [95% CI 1.37-2.41], P = 0.0001) and mortality (1.73 [1.34-2.24], P = 0.0001). Enalapril prevented clinical proteinuria in diabetic patients (0.38 [0.17-0.81], P = 0.0123) but not in nondiabetic patients (1.43 [0.77-2.63], P = 0.2622) without baseline proteinuria. CONCLUSIONS - Clinical proteinuria is an independent predictor of hospitalization for CHF and mortality in diabetic and nondiabetic patients with LV dysfunction. Enalapril significantly reduces the risk of clinical proteinuria in diabetic patients with LV dysfunction.
引用
收藏
页码:377 / 380
页数:4
相关论文
共 25 条
[1]   Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria [J].
Ahmad, J ;
Siddiqui, MA ;
Ahmad, H .
DIABETES CARE, 1997, 20 (10) :1576-1581
[2]  
Boner G, 1996, DIABETOLOGIA, V39, P587
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure [J].
Crepaldi, G ;
Carta, Q ;
Deferrari, G ;
Mangili, R ;
Navalesi, R ;
Santeusanio, F ;
Spalluto, A ;
Vanasia, A ;
Villa, GM ;
Nosadini, R .
DIABETES CARE, 1998, 21 (01) :104-110
[5]   ENHANCED URINARY-EXCRETION OF ALBUMIN IN CONGESTIVE-HEART-FAILURE - EFFECT OF ACE-INHIBITION [J].
EISKJAER, H ;
BAGGER, JP ;
MOGENSEN, CE ;
SCHMITZ, A ;
PEDERSEN, EB .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1992, 52 (03) :193-199
[6]   Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes - The MICRO-HOPE Study [J].
Gerstein, HC ;
Bosch, J ;
Pogue, J ;
Taylor, DW ;
Zinman, B ;
Yusuf, S .
DIABETES CARE, 1996, 19 (11) :1225-1228
[7]  
GRIMM RH, 1997, KIDNEY INT S63, V52, pS10
[8]   Risk of developing end-stage renal disease in a cohort of mass screening [J].
Iseki, K ;
Iseki, C ;
Ikemiya, Y ;
Fukiyama, K .
KIDNEY INTERNATIONAL, 1996, 49 (03) :800-805
[9]   THE PROGNOSTIC-SIGNIFICANCE OF PROTEINURIA - THE FRAMINGHAM-STUDY [J].
KANNEL, WB ;
STAMPFER, MJ ;
CASTELLI, WP ;
VERTER, J .
AMERICAN HEART JOURNAL, 1984, 108 (05) :1347-1352
[10]   THE BENEFICIAL EFFECT OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION WITH CAPTOPRIL ON DIABETIC NEPHROPATHY IN NORMOTENSIVE IDDM PATIENTS WITH MICROALBUMINURIA [J].
LAFFEL, LMB ;
MCGILL, JB ;
GANS, DJ .
AMERICAN JOURNAL OF MEDICINE, 1995, 99 (05) :497-504